- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05925621
Cognitive Neurology Unit Clinical Registry
Cognitive Neurology Unit's Anti-amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease Clinical Registry
Study Overview
Detailed Description
Alzheimer's disease (AD) is a neurodegenerative disorder associated with brain deposition of extracellular amyloid and intracellular tau. It causes progressive cognitive impairment, especially memory, and is invariably fatal. Currently, there is no effective treatment for AD. A new and promising method involves the use of anti-amyloid-beta monoclonal antibodies (anti-amyloid mAbs) to reduce amyloid accumulation in brain. There are currently two anti-amyloid mABs, aducanumab and lecanemab, approved by the FDA under FDA's "accelerated approval" pathway. However, so far there is only a single phase 3 study that unequivocally demonstrates clinical efficacy of anti-amyloid mAB therapy1. This study is designed to help determine the therapeutic benefit of anti-amyloid mABs therapy by treating AD patients in our clinic with anti-amyloid mABs and measuring cognitive impairment and functional outcomes over the course of the treatment period and beyond. This study has 4 specific aims.
SPECIFIC AIM 1: TO CREATE A CNU ANTI-AMYLOID MONOCLONAL ANTIBODY REGISTRY
SPECIFIC AIM 2: TO DETERMINE WHETHER ANTI-AMYLOID MABs SLOW COGNITIVE AND FUNCTIONAL DECLINE
SPECIFIC AIM 3: TO IDENTIFY ANY ASSOCIATIONS BETWEEN SIDES EFFECTS AND PATIENT CHARACTERISTICS
SPECIFIC AIM 4: TO ESTABLISH THE TIME COURSE OF CLINICAL BENEFITS
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Dan Z Press, MD
- Phone Number: (617) 667-4074
- Email: dpress@bidmc.harvard.edu
Study Contact Backup
- Name: Chun Lim, MD
- Phone Number: (617) 667-4074
- Email: clim@bidmc.harvard.edu
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Recruiting
- Beth Israel Deaconess Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
We will enroll patients under the care of the CNU. All patients with a concern for cognitive impairment secondary to AD interested in receiving anti-amyloid monoclonal antibody therapy will be enrolled into this registry as required by CMS.
- Patients with a diagnosis of AD based on National Institute on Aging and the Alzheimer's Association diagnostic guidelines.
- Patients with a diagnosis of MCI based on the National Institute on Aging and the Alzheimer's Association and Petersen criteria.
- All patients eligible to receive anti-amyloid therapy will have confirmation of AD through a positive amyloid PET.
Description
Inclusion Criteria:
o Patient meets clinical criteria for mild cognitive impairment or early dementia from Alzheimer's disease
- Patient has evidence of cognitive impairment on neuropsychological testing
- Patient has not progressed to the moderate stage of dementia based on neuropsychological testing or clinical judgement
- Amyloid PET imaging and/or CSF analysis consistent with Alzheimer's disease
- Amyloid PET imaging positive
- CSF p-Tau/Abeta42 ration >0.023 and ABeta42 < 1027**
- 3T MRI in past 6 months
- Patient has a care partner
- Patient under the care of an appropriate BI-Lahey amyloid clinic
- Patient is on a stable medication regimen
Exclusion Criteria:
o Recent stroke or suspected TIA in the past year
- Pregnancy
- Active autoimmune or immunological disease
- Systemic treatment with immunosuppressants, immunoglobulins, or monoclonal antibodies or their derivatives
- Bleeding disorder with Plts < 50,000 or INR > 1.5
- On warfarin, heparin, or DOAC
- On dual antiplatelet therapy
- Non Alzheimer disease cause of dementia/MCI
- ApoE e4 homozygote
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Lecanemab
Patients with Alzheimer Disease receiving anti-amyloid mAb therapy at the BIDMC
|
Observational study
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To Determine Whether Anti-Amyloid Mabs Slow Cognitive And Functional Decline
Time Frame: 30 months
|
This study is a prospective, registry-based, single unit, observational study comparing clinical outcome in patients receiving anti-amyloid mAb therapy to historical norms.
|
30 months
|
To Identify Any Associations Between Side Effects And Patient Characteristics
Time Frame: 30 months
|
This study is a prospective, registry-based, single unit, observational study comparing anti-amyloid mAb therapy patient demographics to clinical outcomes.
|
30 months
|
To Establish The Time Course Of Clinical Benefits
Time Frame: 30 months
|
This study is a prospective, registry-based, single unit, observational study examining anti-amyloid mAb therapy patient clinical outcomes and adverse effects over time.
|
30 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023P000494
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Supporting Information Type
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on Lecanemab
-
Eisai Inc.BiogenActive, not recruitingAlzheimer's DiseaseUnited States, Canada, France, Germany, Italy, Japan, Korea, Republic of, Netherlands, Spain, Sweden, United Kingdom
-
HealthPartners InstituteEnrolling by invitation
-
Eisai Inc.CompletedHealthy VolunteersUnited States
-
Eisai Inc.Completed
-
Washington University School of MedicineAlzheimer's Association; Eisai Inc.Not yet recruitingDementia | Alzheimer's Disease | Alzheimer's Disease, FamilialUnited States, Australia, United Kingdom
-
Eisai Inc.BiogenActive, not recruitingEarly Alzheimer's DiseaseUnited States, Spain, Korea, Republic of, China, United Kingdom, Australia, Canada, France, Germany, Italy, Japan, Russian Federation, Singapore, Sweden
-
Washington University School of MedicineNational Institute on Aging (NIA); Alzheimer's Association; Eisai Inc.; Accelerating...RecruitingDementia | Alzheimers Disease | Alzheimers Disease, FamilialUnited States, Canada, Italy, Argentina, Australia, Colombia, Netherlands, Puerto Rico, Spain, United Kingdom, France, Ireland, Mexico, Brazil, Japan, Germany
-
Eisai Inc.National Institute on Aging (NIA); Biogen; Alzheimer's Clinical Trials ConsortiumRecruitingPreclinical Alzheimer's Disease | Early Preclinical Alzheimer's DiseaseUnited States, Singapore, Canada, Spain, Australia, Japan, United Kingdom, Sweden, Netherlands
-
Ali RezaiInSightecRecruitingMild Cognitive Impairment | Alzheimer Disease 1United States
-
Emory UniversityCenters for Medicare and Medicaid ServicesRecruiting